Bicycle Therapeutics plc BCYC

Company Overview

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing a class of therapeutics known as bicyclic peptides, which the company refers to as “Bicycles.” The company operates primarily in the oncology and radiopharmaceutical sectors, with additional research activity in areas such as autoimmune and inflammatory diseases. Bicycle Therapeutics is publicly traded on Nasdaq under the ticker BCYC and is headquartered in Cambridge, United Kingdom, with significant operational presence in the United States.

The company’s core business centers on the discovery and development of targeted therapeutics designed to combine the pharmacological properties of biologics with the manufacturing and tissue penetration advantages of small molecules. Its primary revenue sources have historically included collaboration agreements, licensing arrangements, and milestone payments with pharmaceutical partners, while its long-term strategy is centered on commercialization of internally developed therapies. Bicycle Therapeutics was founded in 2009 as a spinout from the Medical Research Council Laboratory of Molecular Biology in Cambridge and evolved from platform discovery research into a clinical-stage oncology developer with multiple drug candidates in human trials.